BioMediTech Research Infrastructure

iPS Cells

iPS Cells facility is located in the Arvo building on the Kauppi campus of the University of Tampere. The facility provides services related to iPS cell technology for academic and non-academic clients.


Already fully differentiated adult cells can be reprogrammed into pluripotent cells in defined conditions. Reprogrammed cells are called induced pluripotent stem cells, iPS cells, and they can be differentiated into desired cell type, retaining the original genotype. With this technology, it is possible to create patient specific stem cell lines, which provide a way to model and study the pathophysiology of various disorders in human cells. Therefore, iPS cell technology offers a promising and safe platform to screen and optimize patient specific drug therapy.

iPS Cells facility is located in the Arvo building on the Kauppi campus of the Tampere University. The facility provides services related to iPS cell technology for academic and non-academic clients.

iPS cells


All the users of the iPS Cells facility services are obligated to acknowledge the facility in publications:

“The authors acknowledge the Tampere facility of iPS Cells for their service.”


We have optimized both integrative as well as non-integrative reprogramming methods at the iPS Cells facility. iPS cells can be reprogrammed using either retroviruses or non-viral methods (e.g. episomal vectors). Reprogramming has been optimized for fibroblasts.

The iPS cells have the capacity to differentiate into derivatives from all three germ layers. In defined conditions iPS cells can be differentiated into the cell type of interest including cardiomyocytes, neural cells and hepatocytes.

iPS Cells facility has established novel assays to automatically or semi-automatically analyze the morphology and functionality of cardiomyocytes. The assays include analysis of cell size and orientation, as well as detailed analysis of Ca2+ transients, electrical and beating behavior of the cells. Besides cardiomyocytes, these assays can be applied on many other cell types.


iPS Cells facility provides following services:

  • Taking a skin biopsy
  • Provision of human iPS cells
    • Large collection of disease specific iPS cells, as well as iPS cells derived from healthy control individuals
  • Generation of human iPS cells from fibroblasts provided by client
    • A supportive statement from the ethical committee is required
    • Generation and basic characterization of at least two human iPS cell clones
  • Characterization of human iPS cells
    • pluripotency marker characterization (Nanog, Oct4, TRA-1-60, TRA-1-81)
    • PCR analysis of endogenous and exogenous markers
    • In vitro pluripotency analysis by EB formation
    • karyotype analysis (service bought from outside)
  • Differentiation of human iPS cells upon request
    • cardiomyocytes, hepatocytes
  • Provision of differentiated cells
    • cardiomyocytes, hepatocytes
  • Characterization of differentiated cells
    • Optimized assays for studying the morphology (cell size and orientation) and functionality (Ca2+ transients and basic electrophysiology), as well as beating behavior (video analysis) of differentiated cells
    • Assays have been optimized for the iPS-derived cardiomyocytes but same methods can be applied for other cell types
  • Rent of special equipment
    • 4D-Nucleofector™ System
    • EVOS™ FL Cell Imaging System (light cubes: DAPI, GFP, RFP)
  • Hands-on training
    • iPS Cells facility provides customized hands-on training for clients


Product University of Tampere price Academic price
Skin biopsy 200 € 200 €
iPS cell generation*
from fibroblasts 1080 € 1170 €
Culture of iPS cells (1 passage)
on MEF feeder cell layers 100 € 145 €
in feeder cell-free culture 105 € 150 €
Characterization of iPS cells
immunocytochemistry 200 € 290 €
PCR analysis 150 € 285 €
in vitro pluripotency analysis 200 € 290 €
karyotype analysis upon request upon request
genotype analysis upon request upon request
Differentiation of iPS cells upon request upon request
Analysis of differentiated cells
cell size and orientation upon request upon request
Ca2+ transients upon request upon request
basic electrophysiology upon request upon request
mechanical movement upon request upon request
Hands-on training upon request upon request
Rent of Nucleofector and EVOS systems upon request upon request

* Price for iPS cell generation includes derivation and culture of primary cells, infection and cell culture until iPS cell colonies are picked

VAT is not included in the prices.

Please inquire the prices for non-academic customers.


Facility Director:

Katriina Aalto-Setälä, MD
Tel: +358 40 582 9567
Room: ARVO D437


Kiamehr M, Viiri LE, Vihervaara T, Koistinen KM, Hilvo M, Ekroos K, Käkelä R, Aalto-Setälä K.
Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells.
Dis Model Mech. 2017 Sep 1;10(9):1141-1153.

Kuusela J, Larsson K, Shah D, Prajapati C, Aalto-Setälä K.
Low extracellular potassium prolongs repolarization and evokes early afterdepolarization in human induced pluripotent stem cell-derived cardiomyocytes.
Biol Open. 2017 Jun 15;6(6):777-784. doi: 10.1242/bio.024216.

Vuorenpää H, Penttinen K, Heinonen T, Pekkanen-Mattila M, Sarkanen JR, Ylikomi T, Aalto-Setälä K.
Maturation of human pluripotent stem cell derived cardiomyocytes is improved in cardiovascular construct.
Cytotechnology. 2017 Apr 10. doi: 10.1007/s10616-017-0088-1.

Laurila E, Ahola A, Hyttinen J, Aalto-Setälä K.
Methods for in vitro functional analysis of iPSC derived cardiomyocytes – Special focus on analyzing the mechanical beating behavior.
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1864-72.

Ojala M, Prajapati C, Pölönen RP, Rajala K, Pekkanen-Mattila M, Rasku J, Larsson K, Aalto-Setälä K.
Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy.
Stem Cells Int. 2016;2016:1684792. doi:10.1155/2016/1684792

Juhola M, Penttinen K, Joutsijoki H, Varpa K, Saarikoski J, Rasku J, Siirtola H, Iltanen K, Laurikkala J, Hyyrö H, Hyttinen J, Aalto-Setälä K
Signal analysis and classification methods for the calcium transient data of stem cell-derived cardiomyocytes
Comput Biol Med, 2015, 61:1–7

Kiviaho A, Ahola A, Larsson K, Kujala K, Pekkanen-Mattila M, Venäläinen H, Paavola K, Hyttinen J, Aalto-Setälä, K
Distinct electrophysiological and mechanical beating phenotypes of Long QT syndrome type 1 -specific cardiomyocytes carrying different mutations
IJC Heart & Vasculature, 2015, 8:19-31

Penttinen K, Swan H, Vanninen S, Paavola J, Lahtinen A-M, Kontula K, Aalto-Setälä K
Antiarrhythmic effects of Dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models
PLoS One, 2015, 10(5):e0135806

Penttinen K, Siirtola H, Ávalos-Salguero J, Vainio T, Juhola M, Aalto-Setälä K
Novel analysis software for detecting and classifying Ca2+ transient abnormalities in stem cell-derived cardiomyocytes
PLoS One, 2015, 10(8):e0135806

Kartasalo K, Pölönen R-P, Ojala M, Rasku J, Lekkala J, Aalto-Setälä K, Kallio P
CytoSpectre: a tool for spectral analysis of oriented structures on cellular and subcellular levels
BMC Bioinformatics, 2015, 16:344

Manzini, S, Viiri L, Marttila S, Aalto-Setälä K
A comparative view on easy to deploy non-integrating methods for patient-specific iPSC production
Stem Cell Rev, 2015, 11(6):900-908

Ahola A, Kiviaho A, Larsson K, Honkanen M, Aalto-Setälä K, Hyttinen J
Video image-based analysis of single human induced pluripotent stem cell derived cardiomyocyte beating dynamics using digital image correlation
Biomed Eng Online, 2014, 13:39

Toivonen S, Ojala M, Hyysalo A, Ilmarinen T, Rajala K, Pekkanen-Mattila M, Äänismaa R, Lundin K, Palgi P, Weltner J, Trokovic R, Silvennoinen O, Skottman H, Narkilahti S, Aalto-Setälä K, Otonkoski T
Comparative analysis of targeted differentiation of hiPSC and hESC reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines
Stem Cells Transl Med, 2013, 2(2):89-93

Lahti A, Kujala V, Chapman H, Koivisto A-P, Pekkanen-Mattila M, Kerkelä E, Hyttinen J, Kontula K, Swan H, Conklin B, Yamanaka S, Silvennoinen O, Aalto-Setälä K
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture
Dis Model Mech, 2012, 5(2):220-230

© 2019 | BioMediTech Finland. All rights reserved.